Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
biotech
boston blog main
boston top stories
cancer
cancer drugs
deals
2
×
life sciences
2
×
national blog main
national top stories
san francisco blog main
2
×
san francisco top stories
the column group
2
×
abbvie
allergan aesthetics
alzheimer's disease
astrazeneca
athira pharma
attralus
biontech
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
chiesi farmaceutici
cholestatic liver diseases
click therapeutics
clinical trials
cobimetinib
covid-19
cullinan oncology
cystic fibrosis
daniel o'day
detroit blog main
detroit top stories
diabetic macular edema
diagnostics
dogma therapeutics
dyne therapeutics
eli lilly
escape bio
What
drug
2
×
acquisitions
biggest
bio
build
buy
cancer
ceo
company’s
daniel
debut
despite
dyne’s
family
gilead
hardest
hit
hottest
hunters
ipo
medicines
microbiome
moves
openly
o’day
pipeline
proteins
ras
reels
research
revolution
roundup
sciences
scores
seagen
spoken
targets
way
week
Language
unset
2
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
deals
×
" life sciences "
×
" the column group "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer